Table 3.
Clinicopathological characteristics and genetic concordance of KRAS status in the oligometastatic patients.
| Patient ID | Colon PT KRAS status | MT KRAS status | Age (years) | Gender | BMI (kg/m2) | Histology and pathologic stage at diagnosis, grading | Primary tumor side | Synchronous or metachronous metastatic disease | Type of surgery for metastases | Last follow-up (December 2021) |
|---|---|---|---|---|---|---|---|---|---|---|
| PAT1 | wt | Lung, wt | 72 | F | 19.5 | Adenocarcinoma, pT3pN1apV0 pR0, G2 |
Left | M | Lung left lower lobe wedge resection | Oligometastatic progression to the lung |
| PAT2 | p.G12V, p.G13D | Lung, p.G13D | 78 | M | 19.8 | Adenocarcinoma, pT3pN0pV1 pR0, G2 |
Right | M | Lung left lower lobe wedge resection | Oligometastatic progression to the lung |
| PAT3 | wt | Liver, wt | 82 | F | 21.0 | Adenocarcinoma, pT2pN1bpV0 pR0, G3 |
Right | M | Segment 5 and segment 6 pR0 metastasectomies | NED |
| PAT4 | wt | Lung, wt | 78 | F | 18.2 | Adenocarcinoma, pT3pN1bpV1 pR0, G2 |
Right | M | Lung right lower lobe wedge resection | Polymetastatic progression to the lung |
| PAT5 | p.G12V, p.G13D | Liver, p.G13D | 61 | M | 19.0 | Adenocarcinoma, pT2pN2bpV1 pR0, G2 |
Left | S | Segment 6 pR0 metastasectomy | NED |
| PAT6 | wt | Liver, wt | 27 | F | 18.9 | Adenocarcinoma, pT3pN1bpV1 pR0, G2 |
Right | S | Segment 5 pR0 metastasectomy | NED |
| PAT7 | wt | Liver, wt | 52 | M | 21.2 | Adenocarcinoma, pT2pN1apV1 pR0, G3 |
Left | M | Segment 8 pR0 metastasectomy | NED |
| PAT8 | p.G12D | Lung, wt | 60 | M | 19.9 | Adenocarcinoma, pT3pN0bpV0 pR0, G2 |
Left | M | Lung right upper lobe wedge resection | NED |
| PAT9 | wt | Liver, wt | 47 | F | 20.5 | Adenocarcinoma, pT3pN1apV1 pR0, G3 |
Left | S | Segment 8 pR0 metastasectomy | Oligometastatic progression to the liver |
BMI, body mass index; G, grading; L, left; MT, metastatic tumor; PAT, patient; PT, primary tumor; pR0, no residual disease at microscopic examination after surgery; wt, wild-type.